The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
For the full year FY25, net profit soared 12x to Rs 345 crore
Subscribe To Our Newsletter & Stay Updated
